Multi-epitope
Showing 1 - 25 of >10,000
Prostatic Tumors, Prostate Cancer Trial run by the NCI (Autologus elutriated monocyte vaccine, Multi-epitope (ME) T-cell
Terminated
- Prostatic Neoplasms
- Prostate Cancer
- Autologus elutriated monocyte placebo vaccine
- Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Mar 10, 2022
Advanced Ovarian Cancer Trial in Seattle (AST-201, Paclitaxel, Carboplatin)
Not yet recruiting
- Advanced Ovarian Cancer
- AST-201
- +4 more
-
Seattle, WashingtonUniversity of Washington
Mar 20, 2023
Breast Ductal Carcinoma In Situ Trial in Jacksonville, Rochester (Granulocyte-Macrophage Colony-Stimulating Factor,
Recruiting
- DCIS
- (H2NVAC)
-
Jacksonville, Florida
- +1 more
Jul 7, 2021
Ovarian Cancer Trial in United States (TPIV200, Durvalumab)
Completed
- Ovarian Cancer
- TPIV200
- Durvalumab
-
Basking Ridge, New Jersey
- +4 more
Nov 1, 2021
Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7 Trial in United States (drug, other,
Active, not recruiting
- Bilateral Breast Carcinoma
- +11 more
- Cyclophosphamide
- +4 more
-
Scottsdale, Arizona
- +11 more
Jan 12, 2023
Breast Ductal Carcinoma In Situ Trial in Jacksonville, Rochester (Granulocyte-Macrophage Colony-Stimulating Factor,
Recruiting
- Breast Ductal Carcinoma In Situ
- Granulocyte-Macrophage Colony-Stimulating Factor
- +2 more
-
Jacksonville, Florida
- +1 more
Dec 10, 2021
Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma Trial in Rochester (Biopsy,
Not yet recruiting
- Fallopian Tube Carcinosarcoma
- +14 more
- Biopsy
- +6 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 28, 2023
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Tumor Trial in Rochester
Active, not recruiting
- Fallopian Tube Clear Cell Adenocarcinoma
- +22 more
- Laboratory Biomarker Analysis
- Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
-
Rochester, MinnesotaMayo Clinic
Oct 7, 2022
Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer Trial in Seattle (drug,
Terminated
- Stage III Fallopian Tube Cancer
- +14 more
- Carboplatin
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 17, 2021
Melanoma (Skin) Trial in Philadelphia, Houston, Charlottesville (incomplete Freund's adjuvant, melanoma helper peptide vaccine,
Completed
- Melanoma (Skin)
- incomplete Freund's adjuvant
- +4 more
-
Philadelphia, Pennsylvania
- +2 more
Mar 25, 2021
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7 Trial in United States
Recruiting
- Breast Adenocarcinoma
- +7 more
- Multi-epitope HER2 Peptide Vaccine TPIV100
- +5 more
-
Scottsdale, Arizona
- +26 more
Aug 17, 2022
Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Ovarian Epithelial Cancer Trial in Seattle
Completed
- Stage III Ovarian Epithelial Cancer
- +3 more
- pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine
- laboratory biomarker analysis
-
Seattle, WashingtonFred Hutchinson Cancer Research Center/University of Washington
Feb 22, 2021
Melanoma (Skin) Trial in Charlottesville (biological, drug, procedure)
Completed
- Melanoma (Skin)
- incomplete Freund's adjuvant
- +6 more
-
Charlottesville, VirginiaUniversity of Virginia Cancer Center
Mar 26, 2020
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Cyclophosphamide (Non-IMP, Lymphodepletion)
- +3 more
-
Ulm, Baden-Württemberg, Germany
- +4 more
Jul 24, 2023
Tumors Trial in Tijuana (Neoantigen Peptides)
Recruiting
- Neoplasms
- Neoantigen Peptides
-
Tijuana, Baja California, MexicoInstituto de Medicina Regenerativa
Jul 22, 2022
Prostate Cancer Trial in New York (PGV-001, Poly-ICLC, CDX-301)
Recruiting
- Prostate Cancer
- PGV-001
- +2 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai (ISMMS)
Aug 10, 2021
HIV Trial in Washington (HST-NEETs)
Active, not recruiting
- HIV Infections
- HST-NEETs
-
Washington, District of Columbia
- +2 more
Feb 22, 2022
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, NSCLC Stage IV Trial in Australia, United States (IMU-201
Recruiting
- Non Small Cell Lung Cancer
- +5 more
- IMU-201 (administered as PD1-Vaxx)
-
Phoenix, Arizona
- +5 more
Jan 19, 2022
Nasopharyngeal Carcinoma by AJCC V8 Stage Trial in China (Nimotuzumab, Gemcitabine, Cisplatin)
Recruiting
- Nasopharyngeal Carcinoma by AJCC V8 Stage
- Nimotuzumab
- +3 more
-
Baise, Guangxi, China
- +8 more
Jan 29, 2023
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma Trial in Korea,
Recruiting
- EBV Associated Extranodal NK/T-cell Lymphoma
- EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
- EBViNT Cell
-
Seoul, Gangnam-gu, Korea, Republic of
- +7 more
Jul 7, 2022
HIV-Infected Individuals Trial in Baltimore (DD HST-NEETs)
Recruiting
- HIV-Infected Individuals
- DD HST-NEETs
-
Baltimore, MarylandJohns Hopkins University(Jhu)
Mar 2, 2022
SARS-CoV-2 Infection Trial in Washington (Coronavirus-specific T cell (CST))
Recruiting
- SARS-CoV-2 Infection
- Coronavirus-specific T cell (CST)
-
Washington, District of Columbia
- +1 more
Sep 1, 2022
Chronic Lymphocytic Leukemia, COVID-19 Trial in Toronto (EVUSHELD)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- COVID-19
- EVUSHELD
-
Toronto, Ontario, CanadaSunnybrook Health Sciences Cente
Jul 18, 2022
Peanut Allergy Trial in United States (DBV712 250 mcg)
Enrolling by invitation
- Peanut Allergy
- DBV712 250 mcg
-
Little Rock, Arkansas
- +7 more
Mar 3, 2022
